Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

about

Clinical treatment of newly diagnosed multiple myeloma.

P2860

Q38578071-E2690955-5596-47CB-86E2-20F2F19D3031

P2860

Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Item

http://www.wikidata.org/entity/Q38316150

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Treatment of patients with mul ...... and Scientific Advisory Group.

@en

type

Item

label

Treatment of patients with mul ...... and Scientific Advisory Group.

@en

prefLabel

Treatment of patients with mul ...... and Scientific Advisory Group.

@en

P1476

Treatment of patients with mul ...... and Scientific Advisory Group

@en

P2093

A Spencer

http://www.w3.org/2001/XMLSchema#string

B Augustson

http://www.w3.org/2001/XMLSchema#string

B To

http://www.w3.org/2001/XMLSchema#string

D Joshua

http://www.w3.org/2001/XMLSchema#string

D Talaulikar

http://www.w3.org/2001/XMLSchema#string

H M Prince

http://www.w3.org/2001/XMLSchema#string

H Quach

http://www.w3.org/2001/XMLSchema#string

J Gibson

http://www.w3.org/2001/XMLSchema#string

J Ho

http://www.w3.org/2001/XMLSchema#string

J Szer

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy.

Lenalidomide after stem-cell transplantation for multiple myeloma

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.

Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents

A comparison of allografting with autografting for newly diagnosed myeloma.

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla

P304

94-105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IMJ.12640

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25582938

http://www.w3.org/2001/XMLSchema#string

P921

Australia

Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

about

P2860

P2860

Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921